PacBio (NASDAQ: PACB) posts Q3 2025 results in 8-K filing disclosure

Rhea-AI Filing Summary

Pacific Biosciences of California, Inc. reported that it announced financial results for its third fiscal quarter ended September 30, 2025. The company disclosed that these third-quarter 2025 results, covering its results of operations and financial condition, are presented in a press release titled “PacBio Announces Third Quarter 2025 Financial Results.”

The press release is furnished as Exhibit 99.1 to this report, meaning it provides the detailed quarterly figures and commentary, while the report itself primarily serves to formally notify investors that the results have been released.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001299130false00012991302025-11-052025-11-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

November 5, 2025

Pacific Biosciences of California, Inc.

(Exact name of registrant as specified in its charter)

Delaware			001-34899			16-1590339
(State or other jurisdiction of incorporation)			(Commission File Number)			(IRS Employer Identification No.)

1305 O’Brien Drive

Menlo Park, California 94025

(Address of principal executive offices) (Zip Code)

(650) 521-8000

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

PACB

The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

ITEM 2.02.    RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On November 5, 2025, Pacific Biosciences of California, Inc. (the “Company”) announced its financial results for its third fiscal quarter ended September 30, 2025. A copy of the press release containing the announcement is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

The information furnished in this Item 2.02 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

ITEM 9.01.    FINANCIAL STATEMENTS AND EXHIBITS.

(d)			Exhibits.
99.1			Press Release dated November 5, 2025, titled “PacBio Announces Third Quarter 2025 Financial Results” (furnished and not filed herewith solely pursuant to Item 2.02).
104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Pacific Biosciences of California, Inc.
			By:			/s/ Michele Farmer
						Michele Farmer
						Vice President and Chief Accounting Officer
Date: November 5, 2025

FAQ

What did Pacific Biosciences (PACB) disclose in this 8-K?

Pacific Biosciences of California, Inc. disclosed that it announced its financial results for the third fiscal quarter ended September 30, 2025, as described in an accompanying press release.

Which period do PacBio (PACB) third-quarter 2025 results cover?

The third-quarter 2025 results for PacBio cover the fiscal quarter ended September 30, 2025.

How were PacBio (PACB) Q3 2025 results communicated to investors?

The company communicated its Q3 2025 results through a press release titled “PacBio Announces Third Quarter 2025 Financial Results”, which is furnished as Exhibit 99.1 to this report.

Is the PacBio (PACB) Q3 2025 press release considered filed with the SEC?

No. The company states that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed “filed” for purposes of Section 18 of the Exchange Act, unless specifically incorporated by reference in another filing.

Where can investors find detailed PacBio (PACB) Q3 2025 financial figures?

Detailed financial figures and commentary for PacBio’s third quarter 2025 are contained in Exhibit 99.1, the press release “PacBio Announces Third Quarter 2025 Financial Results.”

What exhibits are included with this PacBio (PACB) 8-K?

The report includes Exhibit 99.1, the third-quarter 2025 financial results press release, and Exhibit 104, the Cover Page Interactive Data File embedded within the Inline XBRL document.